Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin  by Tamaoki, Satoru et al.
European Journal of Pharmacology 779 (2016) 168–176Contents lists available at ScienceDirectEuropean Journal of Pharmacologyhttp://d
0014-29
n Corr
E-m
suzuki-h
okada-m
isobe-mjournal homepage: www.elsevier.com/locate/ejpharPulmonary, gastrointestinal and urogenital pharmacologyDevelopment of an experimental rat model of hyperammonemic
encephalopathy and evaluation of the effects of rifaximin
Satoru Tamaoki a,n, Hiroyuki Suzuki a, Mami Okada a, Norio Fukui b, Mitsui Isobe b,
Tomoyuki Saito a
a Pharmacological Research Department, ASKA Pharmaceutical Co., Ltd., 5-36-1, Shimosakunobe, Takatsu-ku, Kawasaki 213-8522, Japan
b Safety Research Department, ASKA Pharmaceutical Co., Ltd., 5-36-1, Shimosakunobe, Takatsu-ku, Kawasaki 213-8522, Japana r t i c l e i n f o
Article history:
Received 2 November 2015
Received in revised form
10 March 2016
Accepted 11 March 2016
Available online 12 March 2016
Keywords:
Encephalopathy
Hyperammonemia
Animal model
Antibiotics
Gastrointestinal tractx.doi.org/10.1016/j.ejphar.2016.03.024
99/& 2016 The Authors. Published by Elsevie
esponding author.
ail addresses: tamaoki-s@aska-pharma.co.jp (S
3@aska-pharma.co.jp (H. Suzuki),
@aska-pharma.co.jp (M. Okada), fukui-n@ask
@aska-pharma.co.jp (M. Isobe), saito-t1@askaa b s t r a c t
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with hepatic dysfunction.
However, the precise mechanism of HE is unclear. To elucidate the mechanism, we developed a new rat
model of HE with coma using a combination of subcutaneous splenic transposition, partial hepatectomy
and portal vein stenosis. In this model, blood ammonia levels increase in the postcaval vein over time and
markedly increase in the cerebrospinal ﬂuid (CSF). The distribution of ammonia in the various blood
vessels in the HE model suggests that the origin of peripheral blood and CSF ammonia is the mesenteric
veins that drain blood from the gastrointestinal tract. Behavioral analysis revealed decreased pain re-
sponse, increased passivity, and decreased pinna and corneal reﬂexes, followed by the development of
coma. The development of coma in this model was frequent and reproducible. Increased S100 calcium-
binding protein B (S100B: a biomarker for brain injury) in venous blood, as well as damaged brain tissue,
increased intracranial pressure and cerebral edema were observed in rats with coma. A very high cor-
relation was observed between the blood ammonia concentration in the postcaval vein and the onset of
coma. Rifaximin, a poorly absorbed antibiotic that targets gut ﬂora, signiﬁcantly improved symptoms of
HE. Based on these results, our rat model appears to reﬂect the pathological state of HE associated with
acute liver failure and may be a useful model for analysis of hyperammonemic encephalopathy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hepatic encephalopathy (HE) is an important complication of
chronic and acute liver disease (Riordan and Williams, 1997;
Sturgeon and Shawcross, 2014). Previously, HE has been classiﬁed
into three types: Type A, HE associated with acute liver failure
(ALF); type B, HE associated with portal-systemic shunting with-
out hepatocellular disease; and type C, HE associated with un-
derlying cirrhosis and portal hypertension or portal-systemic
shunts (Ferenci et al., 2002). The pathophysiology of HE is not
completely understood, although there is agreement on the im-
portant role of neurotoxins, particularly ammonia (Romero-Gómez
et al., 2015). Ammonia is produced from several organs, such as
kidneys and muscle, and its concentration is highest in the portal
venous system in dog, sheep and horse (Hahn et al., 1893; Nencki
and Zaleski, 1895; Nencki et al., 1896). In humans, portal ammoniar B.V. This is an open access article
. Tamaoki),
a-pharma.co.jp (N. Fukui),
-pharma.co.jp (T. Saito).is presumed to be derived from both the urease activity of the
colonic bacteria and the deamination of glutamine in the small
intestine (Romero-Gómez et al., 2015). Therefore, we examined
the distribution of blood ammonia in rats, given its fundamental
role in the pathology of HE.
In clinical practice, the blood ammonia level is widely used for
diagnosing HE; blood levels correlate with an increased risk of
encephalopathy (Bernal et al., 2007). However, the correlation
between blood ammonia levels and HE severity is not consistent
(Bosoi et al., 2011; Ong et al., 2003; Shawcross et al., 2011). In the
absence of an appropriate animal model of HE, there may be dis-
crepancies between experimental results and clinical signs. For
example, a drug-induced hepatotoxicity model has been shown to
induce deﬁnite pathological lesions, but does not reproduce the
same behavioral signs observed in HE patients (Butterworth et al.,
2009). Coma is an important behavioral change in HE patients and
should be evaluated as a pathognomonic feature (Leise et al., 2014;
Vilstrup et al., 2014). Other models, for example the portal-sys-
temic anastomosis model, require a high degree of microsurgical
skill and lack general versatility (Funovics et al., 1975; Jover et al.,
2005). We thus established a new rat model of HE using an efﬁ-
cient surgical method that resulted in hyperammonemia andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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model and clarify the correlation between blood ammonia levels
and the onset of coma. Rifaximin is an oral, nonsystemic, broad-
spectrum antibiotic that targets gut ﬂora (Bass et al., 2010) and is
used clinically to reduce serum ammonia derived from the gas-
trointestinal (GI) tract. We thus used rifaximin to investigate the
role of ammonia in our HE model.2. Materials and methods
2.1. Animals
All study procedures were carried out after approval of the
protocol by the Animal Research Committee of ASKA Pharma-
ceutical Co., Ltd. based on the criteria, “Rules for the Care and Use
of Laboratory Animals”. Male Sprague Dawley rats (Charles River
Laboratories Japan, Inc., Yokohama) weighing 170–230 g were
used. The animals were maintained at constant temperature
(22 °C) on a 12 h light/dark cycling schedule (8:00 on and 20:00
off) with free access to food and water.
2.2. Drugs
Dosing formulations were freshly prepared on the day of use
and administered orally in doses ranging from 2 to 5 ml/kg. Ri-
faximin was manufactured by Alfa Wassermann S.p.A., Bologna,
Italy. Tween
s
80 was obtained from MP Biomedicals, LLC, Santa
Ana, CA.
2.3. Experimental design and surgical procedure
Following subcutaneous splenic transposition (SST), rats were
orally administered either vehicle (0.5% Tween 80) or rifaximin
(0.3, 3 and 30 mg/kg) once daily for 3 days. Three hours after the
ﬁnal dose, animals underwent 70% partial hepatectomy and portal
vein stenosis to induce encephalopathy. The time of coma onset
was monitored out to 24 h after HE-inducing surgery. Coma was
deﬁned as loss of the righting reﬂex. At the onset of coma or at
24 h after surgery, blood was collected from various vessels for
determination of ammonia concentration.
2.4. Subcutaneous splenic transposition (SST)
SST was performed according to the method described by Di
Domenico et al. (2007). Animals were placed in the dorsal position
under isoﬂurane anesthesia (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) and an approximately 1 cm incision was made on
the skin below the left costal arch. A subcostal pouch was created
laterally in the subcutaneous tissue. The spleen was decapsulized
and placed into the pouch. Animals were allowed to recover for 4–
6 weeks in order to allow for the development of collateral blood
vessels around the spleen.
2.5. Partial hepatectomy and portal vein stenosis
The animals were placed in a dorsal position under isoﬂurane
anesthesia and the abdomen was incised to remove 3 lobes of the
liver (right, left medial and left lateral), which accounted for ap-
proximately 70% of the total liver weight (Nikfarjam et al., 2004).
The portal vein and a stainless steel tube (outer diameter 0.5 mm)
were ligated using a surgical suture. The steel tube was then re-
moved, leaving the vessel ligated to approximately 0.5 mm. In this
manner, blood from the portal vein was shunted into the systemic
circulation.2.6. Determination of ammonia and S100 calcium-binding protein B
(S100B)
The ammonia levels in blood and cerebrospinal ﬂuid (CSF) were
assayed according to the enzymatic cycling method (Yamaguchi
et al., 2005). A small sample (50-100 μl) was taken from the vessel
or cerebral ventricle, mixed with a deproteinizing agent (Kanto
Chemical Co., Inc., Tokyo, Japan) and centrifuged. Ammonia levels
in the supernatant were measured using the Ammonia Assay Kit
(Kanto Chemical Co., Inc., Tokyo, Japan). Serum levels of S100B
were assessed by a sandwich enzyme immunoassay (Rat S100B
ELISA kit, Uscn Life Science Inc., China).
2.7. Behavioral procedures
Behavioral tests were performed by blinded researchers at 1, 6,
12 and 24 h after HE-inducing surgery. Animals were ﬁrst placed
in a transparent box (345403177 mm3) and observed for signs
of abnormal behavior. A battery of Irwin's basic neurological tests
(Irwin, 1968; pain response, pinna reﬂex, corneal reﬂex, righting
reﬂex and passivity) was then performed. Behavioral tests were
scored on a scale of 0–4 (normal score ¼0, maximal score ¼4).
2.8. Histological analysis
Animals were euthanized by exsanguination under anesthesia
at various time points following surgery. The brain was removed
and immediately ﬁxed in 10% neutral buffered formalin. The cer-
ebrum including the hippocampus was trimmed. The tissues were
embedded in parafﬁn wax and sliced into 4 mm sections. Sections
were stained with hematoxylin and eosin for histopathological
examination.
2.9. Intracranial pressure (ICP) monitoring
Following HE-inducing surgery, the midline skin was incised to
expose the atlanto-occipital membrane. The cisterna magna was
stereotaxically punctured with a 25 G needle, which was con-
nected to a pressure transducer via PE50 tubing. The needle was
conﬁrmed to be correctly placed in the subarachnoid space when
ICP immediately increased after applying abdominal pressure. The
punctured site was sealed with a drop of glue to prevent CSF
leakage. A syringe column containing artiﬁcial CSF (115 mM NaCl,
5 mM KCl, 1.5 mM CaCl2, 1.3 mM MgCl2 6H2O, 35 mM NaHCO3,
1.25 mM NaH2PO4 and 10 mM glucose; all chemicals from Sigma-
Aldrich, St. Louis, MO) was also connected to the transducer.
During the procedure, body temperature was monitored using an
intraperitoneal thermistor and maintained at 37 °C with a ventral
heating pad. Under these conditions, ICP was measured con-
tinuously for 12 h.
2.10. Quantiﬁcation of brain water content
At the end of the experiment, animals were euthanized by
exsanguination under anesthesia and the brain was extracted.
Brain tissues were weighed and placed in an electro-thermostatic
baking oven at 105 °C for 48 h until a constant dry weight was
obtained or until the difference between 2 consecutive dry
weights was less than 0.0001 g. The brain water content of each
sample was calculated according to the following formula:
= ( – ) ×Brain water content Wet weight Dry weight /Wet weight
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Statistical analysis was performed using SAS Pre-Clinical Package
Ver. 5.0 (SAS Institute Japan). Dose-response was determined using
analysis of variance (ANOVA) followed by a non-parametric or
parametric Dunnett's multiple comparison test. Comparisons be-
tween groups were made using Student's t-test or the Wilcoxon test.
The coma onset time was monitored out to 24 h after HE-in-
ducing surgery and was analyzed using the Kaplan-Meier method
and a log-rank test. All analyses were performed using Prism 5 for
Windows (version 5.0, GraphPad Software Inc., San Diego, CA).B
120
100
80
60
40
20
0
In
ci
de
nc
e
of
 c
om
a 
(%
)
Experiment 1
Experiment 2
Experiment 3
+
+
+
+ +
+
+
+
2000
1000
0
B
lo
o
SST
Partial hepatectomy
Portal vein stenosis3. Results
3.1. Blood ammonia levels in normal rats
Ammonia concentrations in the blood from the abdominal
aorta and the mesenteric, portal and postcaval veins were ﬁrst
determined in normal rats (Fig. 1). The ammonia concentration in
the abdominal aorta was 62.8713.9 μg/dl. In contrast, mesenteric
venous blood, which drains from the GI tract, contained about a
20-fold higher concentration of ammonia, 1588.47408.7 μg/dl.
The ammonia concentration in the portal blood was
644.17143.2 μg/dl. The blood ammonia level was comparable
between the abdominal aorta and postcaval vein.
3.2. Onset of coma and blood ammonia levels in the HE model
HE was induced in rats by a combination of SST, partial hepa-
tectomy and portal vein stenosis, and blood ammonia concentra-
tions and coma onset were subsequently measured. When either
partial hepatectomy or portal vein stenosis was performed on rats
with SST, no appreciable changes were noted in blood ammonia
concentrations (Fig. 2A). This fact indicates that blood ammonia
produced in the GI tract can be effectively metabolized by ap-
proximately 30% of the liver and may not be affected by hemo-
dynamic changes. Furthermore, in the animals in which the blood0
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Fig. 1. Blood ammonia levels in various blood vessels in normal rats. Ammonia
concentration was measured in blood collected from the abdominal aorta and the
mesenteric, portal and postcaval veins. Data represent the mean7S.D. (n¼8).
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Fig. 2. Blood ammonia levels and coma onset in the HE model. Rats ﬁrst received
SST and then underwent partial hepatectomy and/or portal vein stenosis. Animals
were then monitored for the onset of coma. Ammonia concentration was measured
in blood collected from the abdominal aorta and the mesenteric, portal and post-
caval veins 24 h after the surgery or at the onset of coma. A. Blood ammonia levels
in various blood vessels in rats. Data represent the mean 7 S.D. (n¼7–8).* Po0.05,
** Po0.01,*** Po0.001 compared with the SST group. B. Kaplan-Meier curves of
coma onset time in 3 independent experiments (n¼6-17/experiment).circulation pathway was changed by a combination of SST and
portal vein stenosis, the levels of many serum proteins (aspartate
aminotransferase, alanine aminotransferase, creatine kinase, al-
kaline phosphatase, total bilirubin, total protein, albumin and
creatinine) were comparable to those in normal animals (data not
shown). However, animals with SST followed by both partial he-
patectomy and portal vein stenosis had signiﬁcantly elevated
blood ammonia concentrations in all sampled sites (Fig. 2A). These
animals also became comatose. The incidence of coma after HE-
inducing surgery increased over time (Fig. 2B), reaching 88% or
more in 3 independent experiments (mean ¼97%).
3.3. Effect of rifaximin in the HE model
To clarify the pathological role of GI-derived ammonia in the
development of coma in HE, rats were treated with rifaximin, an
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Fig. 3. Effects of rifaximin on the incidence of coma and hyperammonemia in the
HE model. Rats with SST underwent partial hepatectomy and portal vein stenosis to
induce encephalopathy. The onset time of coma was monitored up to 24 h after
surgery. Ammonia concentration was measured in blood collected from the post-
caval vein at the onset of coma or at 24 h after surgery if no signs of coma were
observed. Rifaximin or vehicle was administered orally beginning 3 days before
surgery. Normal rats were orally administered vehicle during the same period. A.
Effects of rifaximin on blood ammonia levels in HE rats. Data represent the mean
7 S.D. (n¼10). ### Po0.001 compared with the normal group and * Po0.05,***
Po0.001 compared with the vehicle group. B. Kaplan-Meier curves of coma onset
time in HE rats.*** Po0.001 compared with the vehicle group (n¼10).
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ﬂora, thereby decreasing ammonia in the GI tract. In the vehicle
group (0.5% Tween 80), the postcaval ammonia concentration in-
creased 50-fold or more compared with the normal group
(Fig. 3A). Animals treated with rifaximin showed a dose-depen-
dent inhibition of postcaval ammonia concentrations compared
with the vehicle group. In the vehicle group, coma occurred in all
10 animals within 11 h of HE-inducing surgery (Fig. 3B). Incontrast, rifaximin treatment had a dose-dependent effect on
coma onset. In the rifaximin groups, coma appeared in 8 of 10
animals (0.3 mg/kg), 3 of 10 animals (3 mg/kg) and 0 of 10 animals
(30 mg/kg) within 24 h of HE-inducing surgery. Higher doses of
rifaximin (3 and 30 mg/kg) signiﬁcantly inhibited the onset of
coma compared with the vehicle group.
3.4. Behavioral changes in the HE model
Encephalopathy was determined by evaluation of pain re-
sponse, pinna reﬂex, corneal reﬂex and passivity over time (Fig. 4).
Prior to coma onset, decreased pain responses and increased
passivity were noted early after HE-inducing surgery in the vehicle
group. Subsequently, pinna and corneal reﬂexes decreased fol-
lowed by loss of the righting reﬂex, indicating the comatose state.
Rifaximin treatment (0.3–30 mg/kg) reduced all behavioral chan-
ges in a dose-dependent manner. Similar results were obtained in
other behavioral evaluations, such as alertness and locomotor ac-
tivity (data not shown).
3.5. Time course of ammonia levels in the HE model
To better understand to pathological progression of HE, am-
monia levels in the blood and CSF were measured over time. In
addition, serum levels of S100B were measured as a biomarker
indicating brain damage or dysfunction. In the vehicle group, the
blood ammonia concentration in the splenic vein increased im-
mediately after HE-inducing surgery, reaching a level equivalent to
that in the mesenteric vein (Fig. 5A, D). The blood ammonia con-
centration in the postcaval vein increased gradually, reaching 1000
μg/dl or higher 3 h after surgery. The increased ammonia level in
the postcaval vein indicates that portal blood containing high
concentrations of ammonia ﬂowed into the peripheral blood
through the splenic vein and the collateral vessels. The ammonia
concentration in the CSF signiﬁcantly increased at the onset of
coma (Fig. 5B, E). The levels of S100B in the postcaval vein in-
creased with increasing ammonia levels in the CSF during coma
(Fig. 5C, F). Rifaximin treatment led to a decrease in ammonia
levels in blood and CSF and a decrease in S100B levels in blood.
3.6. Histological examination of the brain
We next evaluated brain injury in the HE model by histo-
pathological examination of brain tissues (Fig. 6). In the vehicle
group, vacuolar degeneration of astrocytes and perivascular va-
cuolation in the cerebrum were observed in some animals at 1 h
after surgery and in all animals at 3 h after surgery and at the
onset of coma. Larger areas of damage were observed at the onset
of coma, including vacuolar degeneration of neurons and peri-
neuronal vacuolation (Fig. 6C and D). In animals treated with ri-
faximin 30 mg/kg, very few histopathological changes were ob-
served in the cerebrum.
3.7. ICP and brain weight measurement
We next investigated changes in ICP and brain edema in the HE
model. The ICP of normal rats under isoﬂurane anesthesia de-
creased slightly over a 12 h period. In the vehicle group, ICP
markedly increased 12 h after HE-inducing surgery. This increase
was suppressed in a dose-dependent manner in animals treated
with rifaximin (Fig. 7A). We then turned our attention to brain
edema. The brain was removed at the onset of coma or at 24 h
after surgery to determine water content. In the vehicle group, the
water content of the brain profoundly increased after surgery. The
increase in brain water content was suppressed in a dose-depen-
dent manner in animals treated with rifaximin (Fig. 7B).
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In the HE model, the correlation between the time to coma
onset and the ammonia concentration in the postcaval vein during
coma was investigated. Data from 3 independent experiments
were combined. A signiﬁcant correlation between the time to
coma onset and ammonia concentration was observed, with a
correlation coefﬁcient of 0.6445 (Po0.0001, Fig. 8).4. Discussion
In order to better understand the pathophysiology of HE in
humans, we designed a new animal model of HE. We began our
investigations by examining ammonia levels in various blood
vessels, as this would provide insight into the origin of hyper-
ammonemia in HE. In normal rats, blood ammonia levels were
comparable to those commonly observed in humans (Dam et al.,
2011; Ong et al., 2003). We found that the ammonia concentration
in portal blood was higher than that in venous blood, conﬁrmingprevious ﬁndings that ammonia derived from the GI tract is ulti-
mately drained into the portal blood. We further found that the
ammonia concentration in mesenteric venous blood, which ﬂows
directly from the GI tract to the portal vein, was signiﬁcantly
higher (twice or more) than in portal blood. This fact strongly
suggests that the major source of blood ammonia is the GI tract
(Nencki et al., 1896; Romero-Gómez, 2005). In the HE model, the
ammonia concentration in mesenteric venous blood was more
than 10-fold higher than that in venous blood, and was higher
than venous concentrations observed in HE patients (Kramer et al.,
2000; Ong et al., 2003). These ﬁndings indicate that ammonia
derived from the GI tract may be a major cause of HE-associated
pathology. The primary source of ammonia in the GI tract is en-
teric bacteria, suggesting that interfering with gut ﬂora, for ex-
ample with rifaximin, may decrease GI-derived ammonia and thus
decrease blood ammonia levels and HE-associated pathology.
To generate our experimental HE model, we ﬁrst transposed
the spleen to the subcutis to achieve a portal venous shunt. After a
4-week recovery period, we conﬁrmed the presence of new col-
lateral vessels around the spleen and veriﬁed blood ﬂow between
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cally narrowed the portal vein, re-routing portal blood ﬂow back
into the splenic vein and then into the peripheral circulation
through the new collateral vessels. This blood ﬂow pattern
corresponds to other experimental methods that use bypass graft
surgery to achieve a portal-systemic shunt. After SST and portal
vein stenosis, hepatic function and serum chemistry values were
normal, and animal behaviors were comparable to normal rats.
Finally, we partially resected the liver to limit ammonia metabo-
lism. The combination of SST, portal vein stenosis, and partial
hepatectomy markedly increased ammonia concentration in the
venous blood and led to behavioral changes, including coma.
These changes mirrored behavioral changes observed in patients
with HE. In contrast to the non-coma inducing experimental
models in which liver ﬁbrosis is induced with a choline-deﬁcient
diet or with substances containing carbon tetrachloride or thioa-
cetamide (Bengtsson et al., 1987; Méndez et al., 2009; Molinengo
et al., 1997), our model has the advantage of allowing analysis of
encephalopathy progression. Furthermore, our method uses a
simple surgical technique that efﬁciently alters blood circulation
without the need for special bypass graft surgery (portacaval
shunting). Animals that underwent HE-inducing surgery exhibited
decreased pain response, increased passivity, decreased pinna and
corneal reﬂexes, and ﬁnally became comatose. These behavioral
changes are similar to those observed prior to coma in patients
with chronic liver disease (Vilstrup et al., 2014). Blood ammonia
concentration was highest in the mesenteric vein, followed by thesplenic and postcaval veins. Interestingly, the blood ammonia
concentration in the postcaval vein exceeded 1000 μg/dl and the
concentration in the CSF markedly increased 3 h after surgery. In
addition, increased serum levels of S100B, a known index of brain
damage (Rothermundt et al., 2003; Wiltfang et al., 1999), in the
postcaval vein correlated with increased ammonia concentration
in the CSF. We thus investigated histopathological evidence of
brain damage in our model. We observed cerebral lesions con-
sisting of vacuolar degeneration of astrocytes. Vacuolation was
observed in the perinuclear region of astrocytes and in the peri-
vascular astrocyte foot processes. Moreover, neuronal vacuolar
degeneration was observed. These changes are similar to those
observed in other HE models, in which astrocyte swelling, Alz-
heimer type II astrocytes, and perivascular vacuolization have
been reported (Jayakumar et al., 2011; Matkowskyj et al., 1999;
Pilbeam et al., 1983). It has previously been suggested that the
primary pathogenesis of astrocyte swelling is an increase in blood
ammonia concentration which triggers oxidative stress, enhanced
mitochondrial permeability transition and activation of signaling
kinases (Jayakumar et al., 2011; Norenberg et al., 2007). Together,
these ﬁndings suggest that cerebral damage and related behavioral
changes in our HE model are attributable to astrocyte abnormal-
ities caused by increased blood ammonia concentration.
In addition to increased ammonia concentration in the venous
blood and coma, increased ICP and brain edema have been re-
ported in patients with ALF (Murphy et al., 2004; Chan et al., 2009;
Scott et al., 2013). We thus sought to determine if similar changes
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E F
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Fig. 6. Representative photomicrographs of the cerebral cortex (left) and hippocampus (right) in the HE model. Normal morphology was observed in the cerebrum in the
normal group (A, B). In HE animals treated with vehicle, vacuolar degeneration of astrocytes or neurons (arrows) was observed in the cerebral cortex (C) or hippocampus
(D) and perivascular vacuolation (arrow-head) was observed in the cerebral cortex (C) at the onset of coma. In HE animals treated with rifaximin 30 mg/kg (E, F), no
histopathological changes were observed in the cerebrum. Bar ¼50 mm.
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ICP and brain edema were present in animals that developed coma
and correlated with elevated CSF ammonia concentrations. Our
ﬁndings suggest that elevated ammonia levels play an important
role in encephalopathy. Blood ammonia levels have recently been
shown to correlate with HE severity (Kramer et al., 2000; Ong
et al., 2003). Interestingly, we found that acute coma occurred
when postcaval blood ammonia concentration exceeded 500 μg/
dl. Additionally, we found a correlation between ammonia con-
centration in the venous blood and time to coma onset. Hence, our
model may be a useful tool with which to investigate the re-
lationship between blood ammonia concentration and HE asso-
ciated with ALF. The endpoint of this study was the development
of coma, and future studies will investigate encephalopathy re-
covery after releasing stenosis and ameliorating hyper-
ammonemia. The model may also be used to study subacute HE by
titrating blood ammonia levels and evaluating subsequent changes
in brain function.
Rifaximin is a derivative of rifamycin, which inhibits bacterial
DNA-dependent RNA polymerase and has in vitro activities against
many aerobic and anaerobic gram-positive and gram-negative
bacteria. The bioavailability of rifaximin after oral administration is
less than 0.5%. A recent pharmacological study reported thatrifaximin improved hyperammonemia and normalized brain am-
monia levels in cirrhotic rats (Òdena et al., 2012). Thus, we eval-
uated the validity of our HE model using rifaximin. First, we dosed
rifaximin to normal rats and conﬁrmed a signiﬁcant decrease in the
ammonia concentration in mesenteric venous blood (data not
shown). In the HE model, rifaximin decreased blood ammonia
concentrations and decreased the incidence of coma. These results
suggest that GI-derived ammonia is an important source of blood
ammonia concentration and HE onset. Since rifaximin alters the
intestinal ﬂora and reduces bacterial translocation, further research
is needed to address these speciﬁc effects on HE. On the other hand,
glutaminase is known to produce ammonia in the GI tract and high
glutaminase activity has been reported in HE patients (Romero-
Gómez et al., 2004). It will thus be important to determine the ef-
fects of rifaximin on glutaminase activity in our HE model.
In conclusion, we developed a new animal model to investigate
the pathologic role of hyperammonemia in HE. HE is a complex
pathological state accompanied by personality changes and in-
tellectual disability. Our model reﬂects both the physiologic and
behavioral changes of HE associated with ALF, and recapitulates
the clinical beneﬁts of rifaximin treatment. In future studies, the
model may be used to further elucidate the pathogenesis of HE
associated with hyperammonemia.
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Fig. 7. ICP and water content of the brain in the HE model and the effects of ri-
faximin. A. ICP was measured up to 12 h after HE surgery. Rifaximin or vehicle was
administered orally beginning 3 days prior to surgery. Normal rats were orally
administered vehicle during the same period. Data represent mean ICP (%, n¼6–8).
*** Po0.001 compared with the vehicle group, ### Po0.001 compared with the
normal group. B. Water content was measured in brain tissue collected at the onset
of coma or at 24 h after surgery if no signs of coma were observed. Data represent
the mean 7 S.D. (n¼8–9).*** Po0.001 compared with the vehicle group and ###
Po0.001 compared with the normal group.
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Fig. 8. Correlation between the onset time of coma and blood ammonia levels in
the HE model. Data obtained from 3 independent experiments are shown as
scattergrams (n¼4–18/experiment). The correlation coefﬁcient between the onset
time of coma and blood ammonia level was 0.6455 (Po0.0001).
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